Favorable pathological response with enfortumab vedotin plus toripalimab as neoadjuvant therapy for HER2-negative muscle-invasive bladder cancer: a case report
Xi Zhang, ErChang Shen, Chao Cheng, Rui Meng, Chao Liu, Qiang Shao · 2026
Read Favorable pathological response with enfortumab vedotin plus toripalimab as neoadjuvant therapy for HER2-negative muscle-invasive bladder cancer: a case report by Xi Zhang, ErChang Shen, Chao Cheng, Rui Meng, Chao Liu, Qiang Shao (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13350766.txt.
Description
Xi Zhang and co-authors report a single bladder cancer case with a strong response to drug pairing in a 2026 paper. The patient, a man of eighty-three, had muscle-invasive bladder cancer and wanted to keep his bladder. Before surgery, he received three cycles of two drugs: an antibody-drug conjugate and an immune drug, given on a three-week cycle.
Side effects were limited to high blood sugar and a rash, both handled without stopping treatment. Scans afterward showed the mass largely gone, leaving only wall thickening. A scope procedure then sampled the bladder lining and found inflammation but no leftover cancer. The authors call it a favorable pathological response. They present bladder preservation in this selected patient as a workable path and a hypothesis for formal study.
Catalog record
| CREATOR | Xi Zhang, ErChang Shen, Chao Cheng, Rui Meng, Chao Liu, Qiang Shao |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 23 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |